{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01018173: Phase 3 Interventional Completed Diabetes Mellitus Type 2
(2010)
Source URL:
Class:
PROTEIN
Taspoglutide is a glucagon-like peptide-1 agonist was studied in phase III clinical trials for the treatment patients with type 2 diabetes. However, in September 2010 Roche halted Phase III clinical trials due to gastrointestinal intolerability and serious hypersensitivity reactions experienced by some trial participants.
Status:
Investigational
Source:
INN:mozistobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:velaglucerase beta [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:anbenitamab repodatecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:cenvacibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:ebrasodebart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:baloncibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01775462: Phase 2 Interventional Completed X-Linked Hypohidrotic Ectodermal Dysplasia
(2013)
Source URL:
Class:
PROTEIN
